Abstract
Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate howPDbiomarkers can be powerful tools for guiding treatment strategies.We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 2525-2529 |
| Number of pages | 5 |
| Journal | Clinical Cancer Research |
| Volume | 20 |
| Issue number | 10 |
| DOIs | |
| State | Published - 15 May 2014 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Pharmacologic biomarkers in the development of stratified cancer medicine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver